---
search:
  boost: 3
---

# Antiarrhythmics

This is a subcategory of Cardiovascular Agents.

## Decision Tree

- [Antiarrhythmics - Amiodarone](https://forms.office.com.mcas.ms/pages/designpagev2.aspx?auth_pvr=OrgId&auth_upn=anttwaniqua.greer%40gainwelltechnologies.com&origin=OfficeDotCom&lang=en-US&sessionid=dba554c2-2c78-4f60-bee3-f837172c2546&route=GroupForms&subpage=design&id=nPhjxpvvj0G9PUHkbAzgaN9UYz8EqmlIs3_TYn4TbXBUM1lMQjdHVFZOQVBYMjREQkdEUDYxSzRJMSQlQCN0PWcu&topview=Preview){ :target="_blank" rel="noopener"}
- [Antiarrhythmics - Multaq](https://forms.office.com.mcas.ms/pages/designpagev2.aspx?auth_pvr=OrgId&auth_upn=anttwaniqua.greer%40gainwelltechnologies.com&origin=OfficeDotCom&lang=en-US&sessionid=dba554c2-2c78-4f60-bee3-f837172c2546&route=GroupForms&subpage=design&id=nPhjxpvvj0G9PUHkbAzgaN9UYz8EqmlIs3_TYn4TbXBUMFhJVUhGNE9CWklFUEdDODVJUElRSEFSSCQlQCN0PWcu&topview=Preview){ :target="_blank" rel="noopener"}

## Formulary

### Preferred

| Preferred                        | Generic Name                                              | Quantity | Time (Days) |
| :------------------------------- | :-------------------------------------------------------- | :------: | :---------: |
| Amiodarone 200mg <sup>QL</sup>   | Amiodarone HCI Tab 200 MG                                 |   816    |     102     |
| Disopyramide <sup>QL</sup>       | Disopyramide Phosphate Cap (all strengths)                |   816    |     102     |
| Dofetilide                       |                                                           |          |             |
| Flecainide <sup>QL</sup>         | Flecainide Acetate Tab (all strengths excl 100 MG)        |   306    |     102     |
| Flecainide <sup>QL</sup>         | Flecainide Acetate Tab 100 MG                             |   612    |     102     |
| Mexiletine <sup>QL</sup>         | Mexiletine HCI Cap (all strengths excl 150 MG)            |   306    |     102     |
| Mexiletine <sup>QL</sup>         | Mexiletine HCI Cap 150 MG                                 |   408    |     102     |
| Norpace CR <sup>QL</sup>         | Disopyramide Phosphate ER Cap (all strengths excl 150 MG) |   612    |     102     |
| Norpace CR <sup>QL</sup>         | Disopyramide Phosphate ER Cap R 150 MG                    |   408    |     102     |
| Propafenone IR, ER <sup>QL</sup> |                                                           |          |             |
| Quinidine IR, ER <sup>QL</sup>   |                                                           |          |             |

### Non-Preferred

| Non-Preferred                            | Generic Name                                   |         Quantity          |        Time (Days)        |
| :--------------------------------------- | :--------------------------------------------- | :-----------------------: | :-----------------------: |
| Amiodarone 100mg and 400mg <sup>QL</sup> | Amiodarone HCI Tab (all strengths excl 200 MG) | Determined pursuant to PA | Determined pursuant to PA |
| Multaq                                   |                                                |                           |                           |

## Authorizations

**Length of Authorizations**: 365 Days

**All Authorizations**: Must be prescribed in accordance with FDA approved labeling

## Criteria

### Non-Preferred

Non-Preferred Criteria

- Must provide documentation of medical necessity beyond convenience for why the patient cannot be changed to a preferred drug (i.e., allergies, drug-drug interactions, contraindications, or intolerances) **OR**
    - For any nonsolid oral dosage formulation: must provide documentation of medical necessity for why patient cannot be changed to a solid oral dosage formulation
- Must have had an inadequate clinical response of at least **30 days** with at least **one preferred** drug
    - For non-preferred extended-release formulations: must provide documentation of an inadequate clinical response with its immediate release formulation (if available)
    - For non-preferred brand names that have preferred generics: must provide documentation of an inadequate clinical response or allergy to two or more generic labelers (if available)

### Subsequent Authorization

Subsequent Authorization Criteria

- Must provide documentation of patient's clinical response to treatment and ongoing safety monitoring

## Links

[Criteria](https://pharmacy.medicaid.ohio.gov/sites/default/files/20230401_UPDL_Criteria%20_APPROVED.pdf#page=21){ :target="_blank" rel="noopener"}

[Preferred Drug List](https://pharmacy.medicaid.ohio.gov/sites/default/files/20230401_UPDL_v7_Approved.pdf#page=12){ :target="_blank" rel="noopener"}

[Quantity Limit List](https://pharmacy.medicaid.ohio.gov/sites/default/files/20230101_Ohio_Medicaid_Quantity_Document_APPROVED.pdf){ :target="_blank" rel="noopener"}
